JDM(SH:603088)2023-04-25 16:00Financial Performance - The company's operating revenue for Q1 2023 was CNY 156,024,724.42, representing a year-on-year increase of 3.88%[5] - The net profit attributable to shareholders for Q1 2023 was CNY 37,824,674.27, reflecting a significant increase of 32.55% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 31,899,392.40, up by 46.88% year-on-year[5] - The basic earnings per share for Q1 2023 was CNY 0.09, an increase of 28.57% year-on-year[5] - Net profit for Q1 2023 reached CNY 37,965,660.46, representing a 33.2% increase from CNY 28,518,811.59 in Q1 2022[25] - Earnings per share for Q1 2023 were CNY 0.09, up from CNY 0.07 in Q1 2022[26] Cash Flow - The net cash flow from operating activities reached CNY 23,708,869.78, a remarkable increase of 517.26% compared to the previous year[5] - The net cash flow from operating activities for Q1 2023 was $23,708,869.78, a significant improvement from a net outflow of $5,682,036.55 in Q1 2022, representing a turnaround of approximately 517%[28] - The total cash inflow from operating activities was $161,491,986.44, compared to $118,563,077.90 in Q1 2022, representing an increase of approximately 36%[28] Assets and Liabilities - The total assets at the end of Q1 2023 amounted to CNY 1,379,193,049.18, which is a 2.77% increase from the end of the previous year[6] - The company reported a total current assets of RMB 1,112,571,295.08 as of March 31, 2023, an increase from RMB 1,074,322,407.80 as of December 31, 2022, representing a growth of approximately 3.2%[19] - The company’s total liabilities decreased slightly to CNY 690,612,932.54 from CNY 693,591,391.41 in the previous year[21] - The company’s total equity attributable to shareholders increased by 6.24% to CNY 679,764,659.10 compared to the end of the previous year[6] - The company's equity increased to CNY 688,580,116.64, compared to CNY 648,484,190.14 in Q1 2022, reflecting improved financial health[21] Research and Development - Research and development expenses increased by 58.68% to CNY 11,497,725.60, driven by higher personnel costs and material expenses[9] - Research and development expenses rose to CNY 11,497,725.60, compared to CNY 7,245,990.62 in the previous year, indicating a focus on innovation[25] Investment Activities - Total cash inflow from investment activities was $154,872,192.01, down from $314,185,950.74 in the same period last year, indicating a decrease of about 51%[28] - The net cash outflow from investment activities was $107,379,897.56, compared to a smaller outflow of $13,019,341.39 in Q1 2022, reflecting a deterioration of approximately 726%[28] - The cash received from investment income was $2,579,992.01, an increase from $1,591,801.24 in Q1 2022, representing a growth of approximately 62%[28] Changes in Control - The company completed a significant equity transfer agreement on September 8, 2022, resulting in a change of control, with the total transfer price amounting to RMB 1,085,276,500[14] - The company’s total liabilities and equity structure will be affected by the recent change in control, with the Ningbo Municipal Government becoming the actual controller[15]